Hospital
De Craig Ranch, LLC
De Craig Ranch, LLC was paid $3.05M by Medicaid between Jan 2018 and Dec 2024, across 69 billing codes. Its largest line is 99284, emergency room visit (serious) — 20% of everything it billed.
33Billing provider infoDE CRAIG RANCH, LLC
LAS VEGAS, NV 89139
LAS VEGAS, NV 89139
33aNPI1922542968assigned 12/09/2016
33bProvider typeGeneral Acute Care Hospital
28Total paid$3.05M
24GClaims148,074
24DCodes billed69
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Nevada
Rank by total paid#22 of 36
Median peer was paid$7.64M
This provider vs. median0.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official BUCK, JOHN controls 11+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 3,912 | $38K | |
| 2019 | 20,018 | $397K | |
| 2020 | 18,529 | $377K | |
| 2021 | 24,711 | $516K | |
| 2022 | 26,757 | $596K | |
| 2023 | 28,564 | $612K | |
| 2024incomplete | 25,583 | $510K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 20% | 7,858 | 6,933 | $610K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 20% | 13,229 | 11,761 | $601K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 19% | 4,881 | 4,385 | $566K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 9.4% | 1,205 | 1,103 | $286K |
| 87428 | 4.6% | 3,683 | 3,449 | $140K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.0% | 4,040 | 3,576 | $91K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.6% | 2,268 | 2,162 | $78K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.3% | 825 | 754 | $69K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.9% | 976 | 912 | $59K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.8% | 3,207 | 2,736 | $55K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.3% | 270 | 243 | $40K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.1% | 2,916 | 2,308 | $32K |
57 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.0% | 8,191 | $32K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,847 | $27K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,400 | $24K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 866 | $23K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,185 | $19K |
| 80053 | Comprehensive metabolic panel | <1% | 3,372 | $18K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,211 | $17K |
| 81025 | <1% | 4,571 | $17K | |
| 80051 | <1% | 4,677 | $16K | |
| 82550 | <1% | 4,758 | $16K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,000 | $14K |
| 84484 | <1% | 2,742 | $13K | |
| 82977 | <1% | 3,543 | $13K | |
| 82150 | <1% | 3,579 | $12K | |
| 82565 | <1% | 4,677 | $12K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,659 | $10K |
| 82947 | <1% | 5,125 | $10K | |
| 84520 | <1% | 4,678 | $10K | |
| 84460 | <1% | 3,327 | $9K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 746 | $9K |
| 84075 | <1% | 3,326 | $9K | |
| 84450 | <1% | 3,328 | $8K | |
| 82247 | <1% | 3,326 | $8K | |
| 82040 | <1% | 3,326 | $8K | |
| 81003 | <1% | 6,782 | $7K | |
| 84155 | <1% | 3,329 | $6K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 250 | $6K |
| 80305 | <1% | 977 | $6K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 254 | $5K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 241 | $5K |
| 83880 | <1% | 317 | $5K | |
| 83605 | <1% | 690 | $4K | |
| 85379 | <1% | 574 | $3K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 633 | $3K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,441 | $2K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 83 | $2K |
| 87420 | <1% | 332 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,477 | $1K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 416 | $1K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 381 | $1K |
| 73610 | <1% | 26 | $735.23 | |
| 96376 | <1% | 73 | $724.08 | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 37 | $715.21 |
| 73630 | <1% | 27 | $686.64 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 21 | $667.17 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,535 | $584.43 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 717 | $451.93 |
| 82805 | <1% | 31 | $310.17 | |
| 84702 | <1% | 39 | $296.98 | |
| 87400 | <1% | 44 | $294.48 | |
| 73030 | <1% | 14 | $225.55 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 46 | $187.20 |
| 36415 | Collection of venous blood by venipuncture | <1% | 167 | $171.65 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 146 | $108.79 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 44 | $40.82 |
| 87210 | <1% | 12 | $23.28 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 100 | $6.25 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBUCK, JOHN (PRESIDENT)
Parent organizationDE CRAIG RANCH, LLC
| Provider | Location | Paid |
|---|---|---|
| HCN Ep Horizon City, LLC | Horizon City, TX | $20.85M |
| De Craig Ranch, LLC | North Las Vegas, NV | $13.97M |
| De Craig Ranch, LLC | Las Vegas, NV | $7.84M |
| Iacc/Ehi NW, LLC | Oklahoma City, OK | $6.14M |
| Iacc/Ehi NW, LLC | Del City, OK | $6.01M |
| Iacc/Ehi NW, LLC | Oklahoma City, OK | $4.30M |
| De Craig Ranch, LLC | Las Vegas, NV | $1.62M |
| Emp Idaho Nampa, LLC | Nampa, ID | $1.38M |
| Iacc/Ehi NW, LLC | Moore, OK | $757K |
| SCL Health Westminster, LLC | Northglenn, CO | $25K |
| SCL Health Westminster, LLC | Littleton, CO | $1K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.